Home » Posts tagged with » Tassos Gianakakos
Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate mavacamten. The US pharma giant is offering to acquire MyoKardia for $225.00 per share in an all-cash deal. Mavacamten is being developed for the treatment of a chronic heart disease […]